These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 10190791)
1. Paclitaxel in the treatment of hormone-refractory prostate cancer. Smith DC; Pienta KJ Semin Oncol; 1999 Feb; 26(1 Suppl 2):109-11. PubMed ID: 10190791 [TBL] [Abstract][Full Text] [Related]
2. Paclitaxel, estramustine, and etoposide in the treatment of hormone-refractory prostate cancer. Pienta KJ; Smith DC Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-72-S15-77. PubMed ID: 9346227 [TBL] [Abstract][Full Text] [Related]
3. Phase I study of paclitaxel and estramustine: preliminary activity in hormone-refractory prostate cancer. Hudes GR; Obasaju C; Chapman A; Gallo J; McAleer C; Greenberg R Semin Oncol; 1995 Jun; 22(3 Suppl 6):6-11. PubMed ID: 7597435 [TBL] [Abstract][Full Text] [Related]
4. Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma. Smith DC; Chay CH; Dunn RL; Fardig J; Esper P; Olson K; Pienta KJ Cancer; 2003 Jul; 98(2):269-76. PubMed ID: 12872344 [TBL] [Abstract][Full Text] [Related]
5. Weekly paclitaxel, estramustine phosphate, and oral etoposide in the treatment of hormone-refractory prostate carcinoma: results of a Minnie Pearl Cancer Research Network phase II trial. Meluch AA; Greco FA; Morrissey LH; Raefsky EL; Steis RG; Butts JA; Hainsworth JD; Cancer; 2003 Nov; 98(10):2192-8. PubMed ID: 14601089 [TBL] [Abstract][Full Text] [Related]
9. A Phase I/II study of weekly paclitaxel and 3 days of high dose oral estramustine in patients with hormone-refractory prostate carcinoma. Ferrari AC; Chachoua A; Singh H; Rosenthal M; Taneja S; Bednar M; Mandeli J; Muggia F Cancer; 2001 Jun; 91(11):2039-45. PubMed ID: 11391583 [TBL] [Abstract][Full Text] [Related]
10. A phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancer. Pienta KJ; Redman BG; Bandekar R; Strawderman M; Cease K; Esper PS; Naik H; Smith DC Urology; 1997 Sep; 50(3):401-6; discussion 406-7. PubMed ID: 9301705 [TBL] [Abstract][Full Text] [Related]
11. Weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in hormone-refractory prostate cancer: in vitro combined effects and a phase II trial. Lin CC; Hsu CH; Hour TC; Cheng AL; Huang CY; Huang KH; Chen J; Pu YS Urol Oncol; 2007; 25(3):207-13. PubMed ID: 17483017 [TBL] [Abstract][Full Text] [Related]
13. Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate. Mackler NJ; Dunn RL; Hellerstedt B; Cooney KA; Fardig J; Olson K; Pienta KJ; Smith DC Cancer; 2006 Jun; 106(12):2617-23. PubMed ID: 16691618 [TBL] [Abstract][Full Text] [Related]
14. Paclitaxel in the treatment of esophageal cancer. Weiner LM Semin Oncol; 1999 Feb; 26(1 Suppl 2):106-8. PubMed ID: 10190790 [TBL] [Abstract][Full Text] [Related]
15. Paclitaxel and concurrent radiation therapy for locally advanced adenocarcinomas of the pancreas, stomach, and gastroesophageal junction. Safran H; Akerman P; Cioffi W; Gaissert H; Joseph P; King T; Hesketh PJ; Wanebo H Semin Radiat Oncol; 1999 Apr; 9(2 Suppl 1):53-7. PubMed ID: 10210540 [TBL] [Abstract][Full Text] [Related]
16. The evolving role of paclitaxel for patients with carcinoma of unknown primary site. Greco FA; Hainsworth JD Semin Oncol; 1999 Feb; 26(1 Suppl 2):129-33. PubMed ID: 10190795 [TBL] [Abstract][Full Text] [Related]
17. The current role and future prospects of paclitaxel in the treatment of small cell lung cancer. Hainsworth JD; Greco FA Semin Oncol; 1999 Feb; 26(1 Suppl 2):60-6. PubMed ID: 10190785 [TBL] [Abstract][Full Text] [Related]
18. Oral estramustine plus oral etoposide in the treatment of hormone refractory prostate cancer patients: a phase II study with a 5-year follow-up. Berruti A; Fara E; Tucci M; Tarabuzzi R; Mosca A; Terrone C; Gorzegno G; Fasolis G; Tampellini M; Porpiglia F; De Stefanis M; Fontana D; Bertetto O; Dogliotti L; Urol Oncol; 2005; 23(1):1-7. PubMed ID: 15885575 [TBL] [Abstract][Full Text] [Related]
19. Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens. Thall PF; Logothetis C; Pagliaro LC; Wen S; Brown MA; Williams D; Millikan RE J Natl Cancer Inst; 2007 Nov; 99(21):1613-22. PubMed ID: 17971530 [TBL] [Abstract][Full Text] [Related]
20. Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-risk prostate cancer: preliminary toxicity analysis of RTOG 99-02. Rosenthal SA; Bae K; Pienta KJ; Sobczak ML; Asbell SO; Rajan R; Kerlin KJ; Michalski JM; Sandler HM; Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):672-8. PubMed ID: 18990504 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]